NEW YORK (GenomeWeb News) – Brahms subsidiary Cezanne will incorporate technology from Lumiphore in its diagnostic tests under two new agreements, Richmond, Calif.-based Lumiphore said today.

Brahms and Cezanne will use the Lumi4-Tb technology in development of current and future diagnostic tests under a non-exclusive agreement. In addition, Cezanne acquired exclusive rights to use the technology in diagnostic tests for Down's Syndrome, including tests for Trisomy 21, 13 and 18, Triploidy, Translocation, and Mosaicism, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.